1-ethyl-6-methoxy-isoquinoline | 100191-91-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: 1-ethyl-6-methoxy-isoquinoline
• 英文别名: 1-Aethyl-6-methoxy-isochinolin；1-Ethyl-6-methoxyisoquinoline
• CAS: 100191-91-1
• 化学式: C₁₂H₁₃NO
• 分子量: 187.241
• InChiKey: URZQBOZNDLPDPO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  22.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  4-ethoxy-1-ethyl-6-methoxy-1,2,3,4-tetrahydro-isoquinoline 在 palladium on activated charcoal 、 1,2,3,4-四氢萘 作用下， 生成 1-ethyl-6-methoxy-isoquinoline
  参考文献：
  名称：

  Vinot, Annales de Chimie (Cachan, France), 1958, vol. <13>3, p. 461,472

  摘要：

  DOI：

文献信息

• UREA-CONTAINING PEPTIDES AS INHIBITORS OF VIRAL REPLICATION
  申请人：Chen Dawei

  公开号：US20090082261A1

  公开（公告）日：2009-03-26

  The invention provides compounds urea-containing peptide compounds of Formula I and the pharmaceutically salts and hydrates thereof. The variables T, R 1 -R 9 , J, L, M, Y, Z, m, n, and t are defined herein. Certain compounds of Formula I are useful as antiviral agents. Certain urea-containing peptide compounds disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more urea containing peptides compounds and one or more pharmaceutically acceptable carriers, excipients, or diluents. Such pharmaceutical compositions may contain a urea containing peptides compound as the only active agent or may contain a combination of a urea containing peptides compound and one or more other pharmaceutically active agents. The invention also provides methods for treating viral infections, including Hepatitis C infections, in mammals.

  本发明提供了含有尿素的多肽化合物，其结构如式I所示，以及它们的药物盐和 hydrates（水合物）。 变量T，R1-R9，J，L，M，Y，Z，m，n和t在此文中定义。式I中的某些化合物作为抗病毒剂是有用的。本文中公开的某些含尿素的多肽化合物是病毒复制的强效和/或选择性抑制剂，尤其是丙型肝炎病毒复制。本发明还提供了包含一个或多个含尿素多肽化合物以及一个或多个药物可接受载体、辅料或稀释剂的药物组合物。这样的药物组合物可以仅含有一个含尿素多肽化合物作为唯一的活性成分，也可以包含一个含尿素多肽化合物与一个或多个其他药物活性成分的组合。本发明还提供了治疗哺乳动物中病毒感染的方法，包括丙型肝炎感染。
• Inhibitors of Hepatitis C Virus
  申请人：D'Andrea Stanley

  公开号：US20080107625A1

  公开（公告）日：2008-05-08

  Macrocyclic peptides are disclosed having the general formula: wherein R 3 , R 3 ′, R 4 , R 6 , R′, X, Q and W are described. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

  揭示了具有一般公式的大环肽： 其中描述了R3、R3'、R4、R6、R'、X、Q和W。还公开了包含这些化合物的组合物以及使用这些化合物抑制HCV的方法。
• Hepatitis C virus inhibitors
  申请人：D'Andrea Stanley

  公开号：US20070099825A1

  公开（公告）日：2007-05-03

  Macrocyclic peptides are disclosed having the general formula: wherein R′, R 3 , R 3′ , R 4 , R 6 , X, Q, and W are described. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

  大环肽被公开，具有一般的公式： 其中R'，R3，R3'，R4，R6，X，Q和W被描述。还公开了包含该化合物的组合物以及使用该化合物抑制HCV的方法。
• Hepatitis C Virus Inhibitors
  申请人：Bristol-Myers Squibb Company

  公开号：US20150023913A1

  公开（公告）日：2015-01-22

  The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

  本公开涉及抗病毒化合物，更具体地涉及能够抑制由丙型肝炎病毒（HCV）编码的NS5A蛋白功能的化合物组合，包括这种组合的组成物，以及抑制NS5A蛋白功能的方法。
• CYCLIC CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF AS OF HEPATITIS C VIRUS
  申请人：Zhang Suoming

  公开号：US20100124545A1

  公开（公告）日：2010-05-20

  The invention provides cyclic carboxamide compounds and analogues thereof of Formula I and the pharmaceutically salts and hydrates thereof. The variables R, R 1 , R 6 -R 8 , R 16 , R 18 , R 19 , M, n, T, Y, and Z are defined herein. Certain compounds of Formula I are useful as antiviral agents. Certain cyclic carboxamide compounds and cyclic carboxamide analogues disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more cyclic carboxamide compounds or cyclic carboxamide analogues and one or more pharmaceutically acceptable carriers. Such pharmaceutical compositions may contain a cyclic carboxamide compound or cyclic carboxamide analogue as the only active agent or may contain a combination of a cyclic carboxamide compound or cyclic carboxamide analogue and one or more other pharmaceutically active agents. The invention also provides methods for treating viral infections, including Hepatitis C infections.

  本发明提供了公式I的环状羧酰胺化合物及其类似物，以及其药物盐和水合物。其中，变量R、R1、R6-R8、R16、R18、R19、M、n、T、Y和Z在此定义。公式I的某些化合物可用作抗病毒剂。本发明所披露的某些环状羧酰胺化合物和环状羧酰胺类似物是有效和/或选择性抑制病毒复制的抑制剂，尤其是乙型肝炎病毒复制的抑制剂。本发明还提供了含有一个或多个环状羧酰胺化合物或环状羧酰胺类似物和一个或多个药用载体的药物组合物。这样的药物组合物可以仅包含一个环状羧酰胺化合物或环状羧酰胺类似物作为唯一活性剂，也可以包含一个环状羧酰胺化合物或环状羧酰胺类似物和一个或多个其他药用活性剂的组合。本发明还提供了治疗病毒感染，包括乙型肝炎感染的方法。